[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624918":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":32,"locations":41,"responsibleParty":61,"collaborators":63,"id":67,"slug":10,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":10,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":10,"enrollmentInfo":75,"targetDuration":10,"studyType":78,"phases":10,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":43,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Virginia Commonwealth University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Retrospective (Kidney Transplant recipients)",null,"There will be 20 Retrospective (Kidney Transplant recipients) subjects enrolled",[13],"Other: Retrospective Cohort Enrollment",{"label":15,"type":10,"description":16,"interventionNames":17},"Prospective (Kidney Transplant recipients)","There will be 30 Prospective (Kidney Transplant recipients) subjects enrolled",[18],"Other: Prospective Cohort Enrollment",[20,24],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"Retrospective Cohort Enrollment","Subjects for this cohort will be selected from existing research database and criteria include:\n\nhx of kidney transplantation, clinically indicated biopsy, positive histology, \\\u003C1% circulating donor-derived cell-free DNA (dd-cfDNA) result at the time of biopsy, and Availability of frozen urine samples.",[9],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"Prospective Cohort Enrollment","Subjects for this cohort will be selected based on ability to provide urine sample, recent kidney transplant recipient and underwent a clinically indicated biopsy",[15],[29],{"name":30,"affiliation":5,"role":31},"Gaurav Gupta, MD","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},"Amber Paulus, PhD","CONTACT","(804) 628-4969","amber.Paulus@vcuhealth.org",{"name":39,"role":35,"phone":10,"phoneExt":10,"email":40},"Gelila Abebe","gelila.abebe@vcuhealth.org",[42],{"facility":5,"status":43,"city":44,"state":45,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Richmond","Virginia","23298","United States",{"type":49,"coordinates":50},"Point",[51,52],-77.46026,37.55376,{"lat":52,"lon":51},[55,58,59],{"name":56,"role":35,"phone":10,"phoneExt":10,"email":57},"Amber Paulus","Amber.Paulus@vcuhealth.org",{"name":39,"role":35,"phone":36,"phoneExt":10,"email":40},{"name":60,"role":31,"phone":10,"phoneExt":10,"email":10},"Gaurav Gupta",{"type":62,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[64],{"name":65,"class":66},"Thermo Fisher Scientific, Inc","INDUSTRY","100624918",false,"NCT07415876","Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA","Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA: Diagnostic Performance and Transport Stability Across Shipping Conditions (CLEAR-CXCL10)","Prospective Inclusion Criteria:\n\n* Age ≥18 years\n* Undergoing a clinically indicated biopsy\n* Able to provide informed consent\n* Willing to provide a urine sample and allow access to relevant clinical\n\nRetrospective Inclusion Criteria:\n\n* Age ≥18 years\n* Biopsy-confirmed rejection (positive histology)\n* Donor-derived cell-free DNA\\\u003C1% result at time of biopsy\n* Availability of stored urine sample collected at time of biopsy\n\nExclusion Criteria (applies to both arms):\n\n* Individuals under 18 years of age\n* Individuals unable to provide informed consent (for prospective enrollment)\n* Pregnant women\n* Prisoners\n* Adults unable to consent","ALL","18 Years",{"count":76,"type":77},50,"ESTIMATED","OBSERVATIONAL","Kidney transplant rejection remains a significant challenge to long-term graft survival. While histological biopsy continues to be the gold standard for diagnosing rejection, noninvasive biomarkers such as donor-derived cell-free DNA (dd-cfDNA) have gained traction for their ability to detect allograft injury. However, dd-cfDNA may lack sensitivity in certain clinical scenarios particularly in cases of localized immune activation leading to false negatives despite biopsy-confirmed rejection.",[81],"Kidney Transplant Rejection",[83,84,85,86,87,88],"CXCL10","CXCR3+T cells","ccfDNA","dd-cfDNA","ABMR","TCMR","2026-06-09",{"date":91,"type":92},"2026-06-10","ACTUAL",{"date":94,"type":92},"2026-06-04",{"date":96,"type":77},"2027-01",{"name":5,"class":6},1]